Previous 10 | Next 10 |
GeoVax Labs (NASDAQ:GOVX) +75% presents COVID-19 vaccine data at the European Society of Medicine (ESMED) General Assembly Marin Software MRIN +25% integrates with Criteo's ecommerce media platform for advertising SunLink Health Systems (NYSE:SSY) +12%. The9 NCTY +9% ...
Fastly FSLY -23% on Q2 earnings release Karyopharm Therapeutics KPTI -18% on Q2 earnings release Fiverr International FVRR -17% on Q2 earnings release Etsy ETSY -13% on Q2 earnings release Maxar Technologies MAXR -13% on Q2 earning...
Are These Penny Stocks on Robinhood Worth Buying This Month? Following the HOOD IPO, penny stocks on Robinhood are once again gaining traction. While HOOD stock going public is not in itself a major catalyst for penny stocks , the momentum that it has seen since then has renewed int...
The USPTO has issued a Notice of Allowance for Alterity Therapeutics' (NASDAQ:ATHE) patent application No. 17/239,375. ATHE shares surge 17.5% premarket to $1.61. The composition of matter patent secures exclusivity for a new group of iron chaperones designed to redistribute th...
BeyondSpring BYSI +336% Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type Wheeler Real Estate (NASDAQ:WHLR) +18%. Robinhood Market...
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's Composition of Matter Patent Covers More than 80 Novel Compounds PR Newswire MELBOURNE, Australia , Aug. 4, 2...
Appendix 4C - Q4 FY21 Quarterly Cash Flow Report PR Newswire Highlights: Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein rela...
Alterity Therapeutics' ([[ATHE]] +2.9%) Multiple System Atrophy treatment ATH434 showed neuroprotective and motor function improvement capabilities in a preclinical study.Multiple System Atrophy ((MSA)) is a rare, neurodegenerative disease with no approved therapy.The publicati...
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function PR Newswire MELBOURNE, Australia , July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), ...
Cinedigm CIDM +31% on Q4 earnings.Huadi International (HUDI) +27%.Verb Technology (VERB) +20%.Datasea (DTSS) +21%.Alterity Therapeutics (ATHE) +17%.Arlo Technologies (ARLO) +13%.Navidea Biopharmaceuticals NAVB +13% surge on regulatory update for rheumatoid arthritis ...
News, Short Squeeze, Breakout and More Instantly...
Alterity Therapeutics Limited Company Name:
ATHE Stock Symbol:
NYSE Market:
Alterity Therapeutics Limited Website:
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...